The clinical efficacy of dabigatran etexilate for preventing stroke in atrial fibrillation patients

Vascular Health and Risk Management

Volumn 9, Issue 1, 2013, Pages 341-352

  Ellis, Christopher R ^a   Kaiser, Daniel W ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Atrial fibrillation; Dabigatran etexilate; NOACs; Stroke; Systemic embolism

Indexed keywords

ACETYLSALICYLIC ACID; AMIODARONE; ANTACID AGENT; ANTITHROMBOCYTIC AGENT; CLARITHROMYCIN; CLOPIDOGREL; DABIGATRAN ETEXILATE; DICLOFENAC; DIGOXIN; ENOXAPARIN; KETOCONAZOLE; MULTIDRUG RESISTANCE PROTEIN; PANTOPRAZOLE; PROTON PUMP INHIBITOR; QUINIDINE; RIFAMPICIN; VERAPAMIL; WARFARIN;

ADVERSE OUTCOME; AREA UNDER THE CURVE; BRAIN HEMORRHAGE; CARDIOVERSION; CATHETER ABLATION; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; CREATININE CLEARANCE; DRUG ABSORPTION; DRUG ADSORPTION; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; DYSPEPSIA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HUMAN; INVASIVE PROCEDURE; KIDNEY DISEASE; LIVER DYSFUNCTION; MAXIMUM PLASMA CONCENTRATION; MECHANICAL HEART VALVE; OUTCOME ASSESSMENT; PARTIAL THROMBOPLASTIN TIME; PERCUTANEOUS CORONARY INTERVENTION; PROTHROMBIN TIME; REVIEW; RISK ASSESSMENT; RISK FACTOR; THROMBOEMBOLISM; TIME TO MAXIMUM PLASMA CONCENTRATION;

ATRIAL FIBRILLATION; DABIGATRAN ETEXILATE; NOACS; STROKE; SYSTEMIC EMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BLOOD COAGULATION; DRUG INTERACTIONS; DRUG MONITORING; DRUG SUBSTITUTION; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; PATIENT SELECTION; PYRIDINES; RISK FACTORS; STROKE; TREATMENT OUTCOME;

EID: 84880627711     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/VHRM.S28271     Document Type: Review

References (58)

1. Coppens M, Eikelboom J W, Gustafsson D, Weitz JI, Hirsh J. Translational success stories: development of direct thrombin inhibitors. Circ Res. 2012;111(7):920-929.
2. Olsson SB; Executive Steering Committee of the SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial. Lancet. 2003;362(9397):1691-1698.
3. Mohapatra R, Tran M, Gore JM, Spencer FA. A review of the oral direct thrombin inhibitor ximelagatran: not yet the end of the warfarin era. Am Heart J. 2005;150(1):19-26.
4. Bates SM, Weitz JI. The mechanism of action of thrombin inhibitors. J Invasive Cardiol. 2000;12 Suppl F:27F-32F.
5. Eriksson BI, Quinlan DJ, Eikelboom J W. Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism. Annu Rev Med. 2011;62:41-57.
6. Becker RC. Cell-based models of coagulation: a paradigm in evolution. J Thromb Thrombolysis. 2005;20(1):65-68.
7. Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest. 1990;86(2):385-391.
8. Weitz JI, Leslie B, Hudoba M. Thrombin binds to soluble fibrin degradation products where it is protected from inhibition by heparin-anti-thrombin but susceptible to inactivation by antithrombin-independent inhibitors. Circulation. 1998;97(6):544-552.
9. Vanassche T, Verhaegen J, Peetermans WE, et al. Inhibition of staphy-lothrombin by dabigatran reduces Staphylococcus aureus virulence. J Thromb Haemost. 2011;9(12):2436-2446.
10. Xiao Z, Théroux P. Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low-molecular-weight heparin and with a direct thrombin inhibitor. Circulation. 1998;97(3):251-256.
11. Ansell J. Warfarin versus new agents: interpreting the data. Hematology Am Soc Hematol Educ Program. 2010;2010:221-228.
12. Wrigley BJ, Lip G Y, Shantsila E. Novel oral anticoagulants: the potential relegation of vitamin K antagonists in clinical practice. Int J Clin Pract. 2010;64(7):835-838.
13. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet. 2008;47(5):285-295.
14. Stangier J, Eriksson BI, Dahl OE, et al. Pharmacokinetic profle of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol. 2005;45(5):555-563.
15. Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacoki-netics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. Br J Clin Pharmacol. 2007;64(3):292-303.
16. Eisert WG, Hauel N, Stangier J, Wienen W, Clemens A, van Ryn J. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Vasc Biol. 2010;30(10):1885-1889.
17. Stangier J, Rathgen K, Stähle H, Mazur D. Infuence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet. 2010;49(4):259-268.
18. Wann LS, Curtis AB, Ellenbogen KA, et al. 2011 ACCF/AHA/HRS focused update on the management of patients with atrial fibrillation (update on dabigatran): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2011;57(11):1330-1337.
19. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos. 2008;36(2):386-399.
20. Stangier J, Stähle H, Rathgen K, Roth W, Shakeri-Nejad K. Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. J Clin Pharmacol. 2008;48(12):1411-1419.
21. Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interactions of warfarin and novel oral anticoagulants: an update. J Thromb Thrombolysis. 2011;31(3):326-343.
22. Stangier J, Stähle H, Rathgen K, Fuhr R. Pharmacokinetics and pharma-codynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet. 2008;47(1):47-59.
23. van Ryn J, Stangier J, Haertter S, et al. Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103(6):1116-1127.
24. Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis. 2012;23(2):138-143.
25. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361(12): 1139-1151.
26. Skanes AC, Healey JS, Cairns JA, et al. Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol. 2012;28(2):125-136.
27. Camm AJ, Lip GY, De Caterina R, et al; ESC Committee for Practice Guidelines-(PG); Document Reviewers 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33(21):2719-2747.
28. Hart RG, Diener HC, Yang S, et al. Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke. 2012;43(6):1511-1517.
29. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365(11):981-992.
30. Patel MR, Mahaffey K W, Garg J, et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365(10):883-891.
31. Eikelboom J W, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation. 2011;123(21):2363-2372.
32. Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials. Arch Intern Med. 2012;172(5):397-402.
33. Hohnloser SH, Oldgren J, Yang S, et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. Circulation. 2012;125(5):669-676.
34. Dans AL, Connolly SJ, Wallentin L, et al. Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. Circulation. 2013;127(5):634-640.
35. Eikelboom J W, Weitz JI. Anticoagulation therapy. Dabigatran and risk of myocardial infarction. Nat Rev Cardiol. 2012;9(5):260-262.
36. Wallentin L, Yusuf S, Ezekowitz MD, et al; RE-LY investigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376(9745):975-983.
37. Beasley BN, Unger EF, Temple R. Anticoagulant options-Why the FDA approved a higher but not a lower dose of dabigatran. N Engl J Med. 2011;364(19):1788-1790.
38. Diener HC, Connolly SJ, Ezekowitz MD, et al; RE-LY study group. Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: A subgroup analysis of the RE-LY trial. Lancet Neurol. 2010;9(12):1157-1163.
39. Birman-Deych E, Radford MJ, Nilasena DS, Gage BF. Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation. Stroke. 2006;37(4):1070-1074.
40. Raji MA, Lowery M, Lin YL, Kuo Y F, Baillargeon J, Goodwin JS. National utilization patterns of warfarin use in older patients with atrial fibrillation: a population-based study of Medicare Part D beneficiaries. Ann Pharmacother. 2013;47(1):35-42.
41. Mercaldi CJ, Ciarametaro M, Hahn B, et al. Cost efficiency of antico-agulation with warfarin to prevent stroke in medicare beneficiaries with nonvalvular atrial fibrillation. Stroke. 2011;42(1):112-118.
42. Healey JS, Eikelboom J, Douketis J, et al; RE-LY Investigators. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation. 2012;126(3):343-348.
43. Wazni OM, Beheiry S, Fahmy T, et al. Atrial fibrillation ablation in patients with therapeutic international normalized ratio: comparison of strategies of anticoagulation management in the periprocedural period. Circulation. 2007;116(22):2531-2534.
44. Winkle RA, Mead RH, Engel G, Kong MH, Patrawala RA. The use of dabigatran immediately after atrial fibrillation ablation. J Cardiovasc Electrophysiol. 2012;23(3):264-268.
45. Lakkireddy D, Reddy YM, Di Biase L, et al. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol. 2012;59(13): 1168-1174.
46. Kaiser DW, Streur MM, Nagarakanti R, Whalen S P, Ellis CR. Continuous warfarin versus peri-procedural dabigatran to reduce stroke and systemic embolism in patients undergoing catheter ablation for atrial fibrillation or left atrial futter. J Interv Card Electrophysiol. [Epub April 28, 2013.]
47. Kim JS, She F, Jongnarangsin K, et al. Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm. 2013;10(4):483-489.
48. Vranckx P, Verheugt F W, de Maat M P, et al. A randomised study of dab-igatran in elective percutaneous coronary intervention in stable coronary artery disease patients. Euro Intervention. 2013;8(9):1052-1060.
49. Ezekowitz MD, Reilly PA, Nehmiz G, et al. Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with non-valvular atrial fibrillation (PETRO Study). Am J Cardiol. 2007;100(9): 1419-1426.
50. Lown B, Perlroth MG, Kaidbey S, Abe T, Harken DE. "Cardioversion" of atrial fibrillation. A report on the treatment of 65 episodes in 50 patients. N Engl J Med. 1963;269:325-331.
51. Jensen JB, Humphries JO, Kouwenhoven WB, Jude JR. Electroshock for atrial futter and atrial fibrillation. Follow-up studies on 50 patients. JAMA. 1965;194(11):1181-1184.
52. Bjerkelund CJ, Orning OM. The efficacy of anticoagulant therapy in preventing embolism related to DC electrical conversion of atrial fibrillation. Am J Cardiol. 1969;23(2):208-216.
53. Fuster V, Rydén LE, Cannom DS, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/ AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114(7):e257-e354.
54. Nagarakanti R, Ezekowitz MD, Oldgren J, et al. Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. Circulation. 2011;123(2):131-136.
55. Van de Werf F, Brueckmann M, Connolly SJ, et al. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN). Am Heart J. 2012;163(6):931-937.
56. Southworth MR, Reichman ME, Unger EF. Dabigatran and postmarket-ing reports of bleeding. N Engl J Med. 2013;368(14):1272-1274.
57. Nagarakanti R, Ellis CR. Dabigatran in clinical practice. Clin Ther. 2012;34(10):2051-2060.
58. Hylek EM, Go AS, Chang Y. Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med. 2003;349(11):1019-1026.